Study of ZIO-201 in Advanced Sarcoma

Advanced Sarcoma Clinical Trial

Official title:
A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma

Status Completed

Clinical Trial Summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00439686
Study type	Interventional
Source	Ziopharm
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	February 2006
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05448820` - YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT04784247` - Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma	Phase 2
Terminated	`NCT03652298` - Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners	Phase 2
Withdrawn	`NCT05238831` - SMMART Adaptive Clinical Treatment (ACT) Trial	Early Phase 1
Active, not recruiting	`NCT04242238` - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	Phase 1
Recruiting	`NCT06087341` - A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma	Phase 1